Myeloablative chemotherapy for recurrent aggressive oligodendroglioma

Neuro-Oncology

Volumn 2, Issue 2, 2000, Pages 114-119

  Cairncross, Gregory ^a,b   Swinnen, Lode ^c   Bayer, Robert ^c   Rosenfeld, Steven ^d   Salzman, Donna ^e   Paleologos, Nina ^f   Kaminer, Lynn ^f   Forsyth, Peter ^g,i   Stewart, Douglas ^h,i   Peterson, Kendra ^j   Hu, Wendy ^j   Macdonald, David ^a,b   Ramsay, David ^a   Smith, Anne ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham Heersink School of Medicine   (United States)

^f EVANSTON HOSPITAL   (United States)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ TOM BAKER CANCER CENTRE   (Canada)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; LOMUSTINE; PCV PROTOCOL; PROCARBAZINE; THIOTEPA; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW DISEASE; BONE MARROW TRANSPLANTATION; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN TUMOR; CACHEXIA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MORTALITY; OLIGODENDROGLIOMA; PATHOLOGY; SURVIVAL; SURVIVAL RATE; TREATMENT FAILURE; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; BONE MARROW TRANSPLANTATION; BRAIN DISEASES; BRAIN NEOPLASMS; CACHEXIA; CEREBRAL HEMORRHAGE; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARNOFSKY PERFORMANCE STATUS; LOMUSTINE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROCARBAZINE; SURVIVAL ANALYSIS; SURVIVAL RATE; THIOTEPA; TREATMENT FAILURE; VINCRISTINE;

EID: 0034173311     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1093/neuonc/2.2.114     Document Type: Article

References (18)

1. Cairncross, J.G., and Eisenhauer, E.A. (1995) Response and control: Lessons from oligodendroglioma. J. Clin. Oncol. 13, 2475-2476.
2. Cairncross, J.G., and Macdonald, D.R. (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23, 360-364.
3. Cairncross, G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T., Buckner, J., Fulton, D., Dropcho, E., Stewart, D., Schold, C., Jr., Wainman, N., and Eisenhauer, E. (1994) Chemotherapy for anaplastic oligodendroglioma. J. Clin. Oncol. 12, 2013-2021.
4. Cairncross, G., Swinnen, L., Stiff, P., Rosenfeld, S., Vaughan, W., Paleologos, N., Kaminer, L., DeAngelis, L., Nimer, S., Dropcho, E., Peterson, K., Forsyth, P., Stewart, D., Weaver, S., Lieberman, F., Macdonald, D., Ramsay, D., and Smith, A. (1997) High-dose thiotepa with hematopoietic reconstitution (deferring radiation) for newly diagnosed aggressive oligodendroglioma. Proc Am. Soc. Clin. Oncol. 16, 388a. (Abstract)
5. Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K., Finkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R., Ino, Y., Ramsay, D.A., and Louis, D.N. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90, 1473-1479.
6. Chamberlain, M.C., and Kormanik, P.A. (1997) Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. J. Clin. Oncol. 15, 3427-3432.
7. Fine, H.A., and Antman, K.H. (1992) High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: Therapeutic rationale and clinical experience, Bone Marrow Transplant 10, 315-321.
8. Glass, J., Hochberg, F.H., Gruber, M.L., Louis, D.N., Smith, D., and Rattner, B. (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV cheomotherapy. J. Neurosurg. 76, 741-745.
9. Kim, L., Hochberg, F.H., Thornton, A.F., Harsh, G.R., IV, Patel, H., Finkelstein, D., and Louis, D.N. (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. 85, 602-607.
10. Levin, V.A., Edwards, M.S., Wright, D.C., Seager, M.L., Schimberg, T.P., Townsend, J.J., and Wilson, C.B. (1980) Modified procarbazine, CCNU, and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 64, 237-244.
11. Macdonald, D.R., Gaspar, L.E., and Cairncross, J.G. (1990a) Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Arch. Neurol. 27, 573-574.
12. Macdonald, D.R., Cascino, T.L., Schuld, S.C., Jr., and Cairncross, J.G. (1990b) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280.
13. Maintz, D., Fiedler, K., Koopmann, J., Rollbrocker, B., Nechev, S., Lenartz, D., Stangl, A.P., Louis, D.N., Schramm, J., Wiestler, O.D., and von Deimling, A. (1997) Molecular genetic evidence for subsets of oligoastrocytomas. J. Neuropathol. Exp. Neurol. 56, 1098-1104.
14. Mason, W.P., Krol, G.S., and DeAngelis, L.M. (1996) Low-grade oligodendroglioma respond to chemotherapy. Neurology 46, 203-207.
15. Mason, W., Louis, D.N., and Cairncross, J.G. (1997) Chemosensitive gliomas in adults: Which ones and why? J. Clin. Oncol. 15, 3423-3426.
16. Peterson, K., Paleologos, N., Forsyth, P., Macdonald, D.R., and Cairncross, J.G. (1996) Salvage chemotherapy for oligodendroglioma. J. Neurosurg. 85, 597-601.
17. Soffietti, R., Ruda, R., Bradac, G.B., and Schiffer, D. (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43, 1066-1073.
18. van den Bent, M.J., Kros, J.M., Heimans, J.J., Pronk, L.C., van Groeningen, C.J., Krouwer, H.G.J., Taphoorn, M.J.B., Zonnenberg, B.A., Tijssen, C.C., Twijnstra, A., Punt, C.J.A., and Boogerd, W. (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 51, 1140-1145.